BioSpace News Archive

LabCorp® announced results for the second quarter ended June 30, 2019, and updated 2019 guidance.

Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced executive management appointments that organizationally support the Company’s long-term strategy.

Mr. Burrell brings cross-sector experience championing value-based healthcare to Intervention Insights’ collaborative, precision medicine platform, Trapelo.™

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its second quarter 2019 financial results will be released after the market closes on Wednesday, August 7, 2019.

A new report released today by the Sabin-Aspen Vaccine Science & Policy Group, a joint initiative of the Sabin Vaccine Institute and the Aspen Institute, calls for an urgent, coordinated effort to amplify and focus resources on the long-sought, but overdue achievement of a universal influenza vaccine (UIV).

HOUSTON, July 25, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has identified a third site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.

Data to be presented at upcoming International Continence Society Annual Meetingin Gothenburg, Sweden in September

The company predominantly assists individuals on behalf of criminal justice systems and judicial treatment programs.

Neurogene Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced it has become the founding sponsor of a new program called “Detect Lysosomal Storage Diseases (LSDs)” from Invitae, a leading medical genetics company.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D, into the role of Executive Chairman of the Board, effective April 1, 2020.